文献速递产科母胎医学

早孕期唐筛假阳性高风险或中风险孕妇的小于胎龄儿预测

First-trimester prediction of small-for-gestational age in pregnancies at false-positive high or intermediate risk for fetal aneuploidy.
PubMed 文献 · Ultrasound Obstet Gynecol · 2020-01-01

这项前瞻性队列研究纳入2053例单胎妊娠,探索早孕期唐氏筛查假阳性高风险或中风险孕妇发生小于胎龄儿(SGA)和胎儿生长受限(FGR)的风险,并评估早孕期筛查对这些结局的预测性能。研究发现,该人群SGA、FGR、早产SGA和早期SGA发生率分别为13.6%、7.9%、6.8%和5.8%,早产SGA算法在此人群中的预测性能优于整体人群。

要点

  • 唐筛假阳性高风险或中风险孕妇SGA发生率为13.6%,FGR为7.9%。
  • 早产SGA算法在该人群预测SGA的AUC为0.8,优于整体人群的0.7。
  • 该人群应进一步筛查SGA以分层胎儿生长异常风险。

核心结论

  • 早孕期唐筛假阳性高风险或中风险孕妇应进一步筛查SGA以分层胎儿生长异常风险。

研究设计与样本

  • 前瞻性队列研究,纳入2053例单胎妊娠孕妇,根据FMF算法计算非整倍体及早产SGA风险。

主要发现

  • 191例(9.3%)为非整倍体高风险或中风险(≥1/1000),304例(14.8%)为早产SGA高风险(≥1/100)。
  • 整体人群中SGA 140例(6.8%)、FGR 61例(3.0%)、早产SGA 44例(2.1%)、早期SGA 33例(1.6%)。
  • 唐筛假阳性高风险或中风险孕妇中SGA 13.6%(26/191)、FGR 7.9%(15/191)、早产SGA 6.8%(13/191)、早期SGA 5.8%(11/191)。
  • 相比早孕期早产SGA低风险孕妇,早产SGA高风险且非整倍体高风险或中风险者的SGA、FGR、早产SGA、早期SGA相对风险分别为6(95%CI 3.9-9)、9.2(95%CI 5.1-16.5)、13.4(95%CI 6.9-26.1)、17.6(95%CI 8.1-38.2)。
  • 非整倍体高风险或中风险孕妇中,早产SGA算法预测SGA的AUC为0.8,高于整体人群的0.7(P<0.001);预测SGA、早产SGA、早期SGA的AUC分别为0.80 vs 0.58(P=0.003)、0.85 vs 0.65(P=0.013)、0.86 vs 0.60(P=0.002),均优于非整倍体算法。

临床怎么用

  • 对早孕期唐筛假阳性高风险或中风险孕妇,可结合早产SGA算法进一步评估胎儿生长异常风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To explore the risk of small-for-gestational age (SGA) and fetal growth restriction (FGR) and to test the performance of first-trimester screening for SGA and FGR in women with a false-positive high or intermediate risk for aneuploidy. METHODS: This was a prospective cohort study of women with a singleton pregnancy attending for a routine first-trimester scan. The risks of aneuploidy and preterm SGA (defined as birth weight < 10th percentile with delivery before 37 weeks) were determined according to Fetal Medicine Foundation algorithms. In non-malformed euploid pregnancies, the predictive performance of both the aneuploidy and preterm SGA risks was evaluated for SGA, FGR (defined as birth weight < 3rd centile), preterm SGA and early SGA (delivery before 34 weeks), using receiver-operating-characteristics (ROC) curve analysis, in those with a high or intermediate risk of aneuploidy and in the overall population. RESULTS: A total of 2053 pregnancies were included in the analysis, of which 191 (9.3%) were at high or intermediate risk for aneuploidy (≥ 1/1000) and 304 (14.8%) were at high risk for preterm SGA (≥ 1/100). In total, there were 140 (6.8%) cases of SGA, 61 (3.0%) of FGR, 44 (2.1%) of preterm SGA and 33 (1.6%) of early SGA. Among women with a false-positive high or intermediate risk for aneuploidy, the rates of SGA, FGR, preterm SGA and early SGA were 13.6% (26/191), 7.9 % (15/191), 6.8% (13/191) and 5.8% (11/191), respectively. Compared with women with a first-trimester low risk for preterm SGA, regardless of aneuploidy risk, those with a high risk for preterm SGA and a high or intermediate risk for aneuploidy had relative risks for SGA, FGR, preterm SGA and early SGA of 6 (95% CI, 3.9-9), 9.2 (95% CI, 5.1-16.5), 13.4 (95% CI, 6.9-26.1) and 17.6 (95% CI, 8.1-38.2), respectively. The predictive performance for SGA of the preterm SGA algorithm was higher in women at high or intermediate risk for aneuploidy than in the overall population (area under the ROC curve (AUC), 0.8 vs 0.7; P < 0.001). Among women at high or intermediate risk for aneuploidy, the predictive performance of the preterm SGA algorithm was better than that of the aneuploidy algorithm for SGA (AUC, 0.80 vs 0.58; P = 0.003), preterm SGA (AUC, 0.85 vs 0.65; P = 0.013) and early SGA (AUC, 0.86 vs 0.60; P = 0.002). CONCLUSION: In women with a first-trimester false-positive high or intermediate risk of aneuploidy, further screening for SGA allows stratification of the risk for fetal growth disorders. Copyright © 2020 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Yarygina TA, Bataeva RS, Benitez L, et al. First-trimester prediction of small-for-gestational age in pregnancies at false-positive high or intermediate risk for fetal aneuploidy. Ultrasound Obstet Gynecol. 2020. PMID: 31909555. doi:10.1002/uog.21965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。